Intermediates

AstraZeneca receives regulatory boost for...

AstraZeneca received a double boost for its oncology portfolio on Tuesday, after US and European regulators accepted regulatory submissions for its drugs, the first step towards winning approval for these medicines. ...

Top 7 Trends In Pharmaceutical Research I...

Being under ever-increasing pressure to compete in a challenging economic and technological environment, pharmaceutical and biotech companies must continually innovate in their R&D programmes to stay ahead ...

ARS-1620: A promising new inhibitor for K...

According to a study published in Cell, researchers have developed a specific inhibitor for KRASG12C called ARS-1602 that induced tumor regression in mice. “This study provides in vivo evidence that mutant KRAS can be...

Intermediates

CPDD1020

CPDD1847

2-AMinopyrazolo[1,5-a]pyriMidine-3-carboxylic acid

CPDD1845

CPDD2013

CPDD1040

CPDD1035

CAS:1708974-56-4,FGF401 Intermediate A9

CPDD1843

CAS:Free1217651-75-6,MSC2530818 Intermediate

CPDD1840

CPDD0277

CPDD2022

2-(1H-imidazol-4-yl)pyridine HCl

CPDD2024

CPDD1623

CPDD2026

CPDD1624

CPD2027

CPDD2017

CPD2028

CPDD2018

CPDD2019

CPDD2020

CPDD2021

AstraZeneca receives regulatory boost for...

Top 7 Trends In Pharmaceutical Research I...

ARS-1620: A promising new inhibitor for K...

AstraZeneca receives regulatory boost for...

Top 7 Trends In Pharmaceutical Research I...